Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination with Docetaxel as Second-Line Treatment in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)

Clinical Lung Cancer

Volumn 17, Issue 2, 2016, Pages e1-e4

  Jänne, Pasi A ^a   Mann, Helen ^b   Ghiorghiu, Dana ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Advanced NSCLC; AZD6244; MEK1 2; Metastatic disease; Phase III

Indexed keywords

DOCETAXEL; PLACEBO; SELUMETINIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; PROTEIN P21; TAXOID;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEMALE; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PLACEBOS; PROTO-ONCOGENE PROTEINS P21(RAS); RESEARCH DESIGN; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961801697     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.12.010     Document Type: Article

References (15)

1. P.J. Roberts, and T.E. Stinchcombe KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31 2013 1112 1121
2. S. Dearden, J. Stevens, Y.L. Wu, and D. Blowers Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) Ann Oncol 24 2013 2371 2376
3. S. Dogan, R. Shen, D.C. Ang, and et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers Clin Cancer Res 18 2012 6169 6177
4. R. Califano, L. Landi, and F. Cappuzzo Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer Drugs 72 Suppl 1 2012 28 36
5. D.A. Eberhard, B.E. Johnson, L.C. Amler, and et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
6. G. Metro, R. Chiari, C. Bennati, and et al. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status Clin Lung Cancer 15 2014 86 92
7. T.C. Yeh, V. Marsh, B.A. Bernat, and et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 13 2007 1576 1583
8. U. Banerji, D.R. Camidge, H.M. Verheul, and et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer Clin Cancer Res 16 2010 1613 1623
9. C.L. Denton, and D.L. Gustafson Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice Cancer Chemother Pharmacol 67 2011 349 360
10. B.R. Davies, A. Logie, J.S. McKay, and et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol Cancer Ther 6 2007 2209 2219
11. S.V. Holt, A. Logie, R. Odedra, and et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models Br J Cancer 106 2012 858 866
12. P.A. Jänne, A.T. Shaw, J.R. Pereira, and et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 2013 38 47
13. Z. Chen, K. Cheng, Z. Walton, and et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 483 2012 613 617
14. E. Dean, N. Steele, H. Arkenau, and et al. A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC Ann Oncol 25 Suppl 4 2014 iv434 iv435
15. G.A. Nicholas, J.R. Goffin, S.A. Laurie, and et al. A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic non-small cell lung cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND 215 NCT01783197 J Clin Oncol 33 Suppl 2015 (Abstract 8046)